Laura Gutierrez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1650132/publications.pdf

Version: 2024-02-01

48 papers

1,765 citations

20 h-index 276875 41 g-index

48 all docs 48 docs citations

48 times ranked

3052 citing authors

#	Article	IF	Citations
1	Clinical Response After Treatment of Knee Osteoarthritis With a Standardized, Closed-System, Low-Cost Platelet-Rich Plasma Product: 1-Year Outcomes. Orthopaedic Journal of Sports Medicine, 2022, 10, 232596712210764.	1.7	5
2	Dissecting platelet proteomics to understand the pathophysiology of immune thrombocytopenia: studies in mouse models. Blood Advances, 2022, 6, 3529-3534.	5.2	7
3	Platelet number and function alterations in preclinical models of sterile inflammation and sepsis patients: implications in the pathophysiology and treatment of inflammation. Transfusion and Apheresis Science, 2022, 61, 103413.	1.0	4
4	Applicability of the Thrombin Generation Test to Evaluate the Hemostatic Status of Hemophilia A Patients in Daily Clinical Practice. Journal of Clinical Medicine, 2022, 11, 3345.	2.4	2
5	Comparison of the PU.1 transcriptional regulome and interactome in human and mouse inflammatory dendritic cells. Journal of Leukocyte Biology, 2021, 110, 735-751.	3.3	3
6	Clinical Management of Hypertension, Inflammation and Thrombosis in Hospitalized COVID-19 Patients: Impact on Survival and Concerns. Journal of Clinical Medicine, 2021, 10, 1073.	2.4	6
7	Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach. International Journal of Molecular Sciences, 2021, 22, 6907.	4.1	10
8	Immunophenotyping and Cell Sorting of Human MKs from Human Primary Sources or Differentiated In Vitro from Hematopoietic Progenitors. Journal of Visualized Experiments, 2021, , .	0.3	0
9	Optimising platelet secretomes to deliver robust tissueâ€specific regeneration. Journal of Tissue Engineering and Regenerative Medicine, 2020, 14, 82-98.	2.7	13
10	Regulation of GATA1 levels in erythropoiesis. IUBMB Life, 2020, 72, 89-105.	3.4	64
11	Platelet-derived bio-products: Classification update, applications, concerns and new perspectives. Transfusion and Apheresis Science, 2020, 59, 102716.	1.0	33
12	In vitro platelet production for transfusion purposes: Where are we now?. Transfusion and Apheresis Science, 2020, 59, 102864.	1.0	8
13	Mild dyserythropoiesis and \hat{l}^2 -like globin gene expression imbalance due to the loss of histone chaperone ASF1B. Human Genomics, 2020, 14, 39.	2.9	2
14	On the Quest for In Vitro Platelet Production by Re-Tailoring the Concepts of Megakaryocyte Differentiation. Medicina (Lithuania), 2020, 56, 671.	2.0	4
15	Sex-dependent grades of haematopoietic modulation in patients with major depressive episodes are associated with suicide attempts. European Neuropsychopharmacology, 2020, 40, 17-30.	0.7	10
16	Neutrophil-to-lymphocyte ratio: A potential new peripheral biomarker of suicidal behavior. European Psychiatry, 2020, 63, e14.	0.2	51
17	The RNA-Binding Protein ATXN2 is Expressed during Megakaryopoiesis and May Control Timing of Gene Expression. International Journal of Molecular Sciences, 2020, 21, 967.	4.1	8
18	Implementation of a closed platelet-rich-plasma preparation method using the local blood bank infrastructure at the Principality of Asturias (Spain): Back to basic methodology and a demographics perspective after 1 year. Transfusion and Apheresis Science, 2019, 58, 701-704.	1.0	6

#	Article	IF	CITATIONS
19	Platelet releasate promotes skeletal myogenesis by increasing muscle stem cell commitment to differentiation and accelerates muscle regeneration following acute injury. Acta Physiologica, 2019, 225, e13207.	3.8	17
20	A comprehensive proteomics study on platelet concentrates: Platelet proteome, storage time and Mirasol pathogen reduction technology. Platelets, 2019, 30, 368-379.	2.3	28
21	Identification of underlying and transfusion-related platelet qualitative alterations in the hemato-oncologic patient. Transfusion and Apheresis Science, 2017, 56, 756-768.	1.0	1
22	Therapy-related myeloid neoplasms as a concerning complication in acute promyelocytic leukemia. Hematology Reports, 2017, 9, 7204.	0.8	4
23	Red blood cell storage time and transfusion: current practice, concerns and future perspectives. Blood Transfusion, 2017, 15, 222-231.	0.4	111
24	Repercussion of Megakaryocyte-Specific Gatal Loss on Megakaryopoiesis and the Hematopoietic Precursor Compartment. PLoS ONE, 2016, 11, e0154342.	2.5	15
25	GATA1-Deficient Dendritic Cells Display Impaired CCL21-Dependent Migration toward Lymph Nodes Due to Reduced Levels of Polysialic Acid. Journal of Immunology, 2016, 197, 4312-4324.	0.8	12
26	Characterization of hematopoietic GATA transcription factor expression in mouse and human dendritic cells. Blood Cells, Molecules, and Diseases, 2015, 55, 293-303.	1.4	6
27	Development of blood transfusion product pathogen reduction treatments: A review of methods, current applications and demands. Transfusion and Apheresis Science, 2015, 52, 19-34.	1.0	99
28	TAF10 Interacts with the GATA1 Transcription Factor and Controls Mouse Erythropoiesis. Molecular and Cellular Biology, 2015, 35, 2103-2118.	2.3	14
29	Sp1/Sp3 transcription factors regulate hallmarks of megakaryocyte maturation and platelet formation and function. Blood, 2015, 125, 1957-1967.	1.4	57
30	Culture of Megakaryocytes from Human Peripheral Blood Mononuclear Cells. Bio-protocol, 2015, 5, .	0.4	6
31	Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Transfusion, 2014, 54, 2292-2300.	1.6	46
32	A novel flow cytometry–based platelet aggregation assay. Blood, 2013, 121, e70-e80.	1.4	131
33	NF-E2 p45 Is Important for Establishing Normal Function of Platelets. Molecular and Cellular Biology, 2013, 33, 2659-2670.	2.3	35
34	Erythropoietic Defect Associated with Reduced Cell Proliferation in Mice Lacking the 26S Proteasome Shuttling Factor Rad23b. Molecular and Cellular Biology, 2013, 33, 3879-3892.	2.3	9
35	The Microtubule Plus-End Tracking Protein CLASP2 Is Required for Hematopoiesis and Hematopoietic Stem Cell Maintenance. Cell Reports, 2012, 2, 781-788.	6.4	35
36	Defects in Glanzmann thrombasthenia and LAD-III (LAD- $1/v$) syndrome: the role of integrin \hat{l}^21 and \hat{l}^23 in platelet adhesion to collagen. Blood, 2012, 119, 583-586.	1.4	35

#	Article	IF	CITATIONS
37	A Dual Reporter Mouse Model of the Human \hat{l}^2 -Globin Locus: Applications and Limitations. PLoS ONE, 2012, 7, e51272.	2.5	12
38	Chronic IFN- \hat{I}^3 production in mice induces anemia by reducing erythrocyte life span and inhibiting erythropoiesis through an IRF-1/PU.1 axis. Blood, 2011, 118, 2578-2588.	1.4	161
39	Vegf regulates embryonic erythroid development through Gata1 modulation. Blood, 2010, 116, 2141-2151.	1.4	23
40	Dynamic regulation of Gata1 expression during the maturation of conventional dendritic cells. Experimental Hematology, 2010, 38, 489-503.e1.	0.4	11
41	Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nature Genetics, 2010, 42, 801-805.	21.4	323
42	Hemopoietic cell expression of the chemokine decoy receptor D6 is dynamic and regulated by GATA1. Journal of Immunology, 2008, 181, 8170.2-8181.	0.8	37
43	Hemopoietic Cell Expression of the Chemokine Decoy Receptor D6 Is Dynamic and Regulated by GATA1. Journal of Immunology, 2008, 181, 3353-3363.	0.8	69
44	Ablation of Gata1 in adult mice results in aplastic crisis, revealing its essential role in steady-state and stress erythropoiesis. Blood, 2008, 111, 4375-4385.	1.4	88
45	Gata1 regulates dendritic-cell development and survival. Blood, 2007, 110, 1933-1941.	1.4	55
46	A hanging drop culture method to study terminal erythroid differentiation. Experimental Hematology, 2005, 33, 1083-1091.	0.4	18
47	Btk Is Required for an Efficient Response to Erythropoietin and for SCF-controlled Protection against TRAIL in Erythroid Progenitors. Journal of Experimental Medicine, 2004, 199, 785-795.	8.5	51
48	Homotypic signalling regulates Gata1 activity in the erythroblastic island. Development (Cambridge), 2004, 131, 3183-3193.	2.5	20